Affinity Map of Bromodomain Protein 4 (BRD4) Interactions with the Histone H4 Tail and the Small Molecule Inhibitor JQ1*

Marie Jung ², Martin Philpott ⁶, Susanne Müller ⁴, Jessica Schulze ¹, Volker Badock ⁴, Uwe Eberspächer ⁸, Dieter Moosmayer ³, Benjamin Bader ⁴, Norbert Schmees ⁵, Amaury Fernández-Montalván ¹ ¹, and Bernard Haendler ⁶

From the ³Global Drug Discovery, Bayer HealthCare, 13353 Berlin, Germany, the ⁴Institute of Chemistry and Biochemistry, Free University, 14195 Berlin, Germany, and ⁵Structural Genomics Consortium and Target Discovery Institute, Nuffield Department of Clinical Medicine, University of Oxford, Oxford OX3 7DQ, United Kingdom

Background: BRD4 is a reader of acetylated histones.

Results: Mutational analysis of BRD4 BD1 allowed the identification of three groups with different binding profiles.

Conclusion: Pro-82, Leu-94, Asp-145, and Ile-146 have a differentiated role in acetyl-lysine and inhibitor interaction.

Significance: Identification of residues essential for BRD4 function will guide the design of novel inhibitors.

Bromodomain protein 4 (BRD4) is a member of the bromodomain and extra-terminal domain (BET) protein family. It binds to acetylated histone tails via its tandem bromodomains BD1 and BD2 and forms a complex with the positive transcription elongation factor b, which controls phosphorylation of RNA polymerase II, ultimately leading to stimulation of transcription elongation. An essential role of BRD4 in cell proliferation and cancer growth has been reported in several recent studies. We analyzed the binding of BRD4 BD1 and BD2 to different partners and showed that the strongest interactions took place with di- and tetra-acetylated peptides derived from the histone 4 N-terminal tail. We also found that several histone 4 residues neighboring the acetylated lysines significantly influenced binding. We generated 10 different BRD4 BD1 mutants and analyzed their affinities to acetylated histone tails and to the BET inhibitor JQ1 using several complementary biochemical and biophysical methods. The impact of these mutations was confirmed in a cellular environment. Altogether, the results show that Trp-81, Tyr-97, Asn-140, and Met-149 play similarly important roles in the recognition of acetylated histones and JQ1. Pro-82, Leu-94, Asp-145, and Ile-146 have a more differentiated role, suggesting that different kinds of interactions take place and that resistance mutations compatible with BRD4 function are possible. Our study extends the knowledge on the contribution of individual BRD4 amino acids to histone and JQ1 binding and may help in the design of new BET antagonists with improved pharmacological properties.

Acetylation of histones is an essential post-translational modification governing gene expression (1, 2). It affects a number of lysine residues in all histones and serves as a docking site for epigenetic readers containing the evolutionarily highly conserved bromodomain module (3). A total of 61 bromodomains found in 46 different proteins have been identified in the human proteome (4). After the recognition of discrete patterns of acetylation marks, which together with neighboring amino acids, mediate binding selectivity, bromodomain-containing proteins engage in a variety of cellular functions. The four bromodomain and extra-terminal domain (BET)³ proteins each contain two related bromodomains named BD1 and BD2 in their N-terminal moiety and a unique, extra-terminal domain. They are highly conserved and form a distinct subfamily with similar hydrophobic binding pockets (5, 6).

Bromodomain protein 4 (BRD4) is the best studied member of the BET family. It is a nuclear protein that binds to acetylated histone 3 (H3) and histone 4 (H4) tails and plays an essential role in maintaining chromatin architecture (7). Through its direct interaction with the acetylated cyclin T1 subunit of the positive transcription elongation factor b, BRD4 furthermore controls transcription elongation via phosphorylation of RNA polymerase II by CDK9 (8–11). Genome-wide studies indicate that BRD4 binding correlates with gene expression and that besides promoter regions, intergenic and intragenic regions are also recognized (12). BRD4 also binds to acetylated RelA, thus stabilizing nuclear NF-κB and controlling the expression of downstream target genes (13, 14). In addition, the BRD4 extra-terminal domain interacts with several chromatin modifiers, including the histone methyltransferase NSD3 (15).

Elucidation of the function of histone acetylation mark readers was much supported by the recent discovery of specific

*This work was supported by the SGC, a registered charity (1097737) that receives funds from AbbVie, Boehringer Ingelheim, the Canada Foundation for Innovation, the Canadian Institutes for Health Research, Genome Canada, GlaxoSmithKline, Janssen, Lilly Canada, the Novartis Research Foundation, the Ontario Ministry of Economic Development and Innovation, Pfizer, Takeda, and the Wellcome Trust (092809/Z/10/2).

Author’s Choice—Final version full access.

Joint last authors.

To whom correspondence should be addressed: Dept. of Chromatin Modulation and Oncogenomics, Therapeutic Research Group Oncology/Gynecological Therapies, Global Drug Discovery, Bayer HealthCare, Müllerstr. 178, D-13353 Berlin, Germany. Tel.: 49-30-468-12669; E-mail: bernard.haendler@bayer.com.

³ The abbreviations used are: BET, bromodomain and extra-terminal domain; BRD4, bromodomain protein 4; H3, histone 3; H4, histone 4; NMC, NUT (nuclear protein in testis) midline carcinoma; SPR, surface plasmon resonance; TSA, thermal shift assay; FP, fluorescence polarization; TR-FRET, time-resolved fluorescence resonance energy transfer; FRAP, fluorescence recovery after photobleaching; BG, background; TAMRA, tetramethylrhodamine; RU, response units.
small-molecule inhibitors (16). BET-selective inhibitors such as JQ1 and I-BET151 (17–19) helped to demonstrate the essential role of BRD4 in growth control. Several BRD4 target genes, including c-Myc, c-Fos, and cyclin D1, are involved in cell cycle control (20–23), and BRD4 binding is much enriched in super-enhancer regions of tumor-associated genes, such as c-Myc and FOSL2 (22). Consequently, BRD4 is implicated in several proliferative diseases. For example, chromosomal translocation leading to the expression of a fusion between BRD4 (or BRD3) and the nuclear protein in testis (NUT) is causative of a rare cancer form named NUT midline carcinoma (NMC) (24, 25). Patient-derived NMC tumors are inhibited by the BET inhibitor JQ1 in

VOLUME 289 • NUMBER 13

/affinity determinants of BRD4 bromodomain binding

As the first BET inhibitors have just entered the clinic, no drug-induced resistance mutation has yet been described. Nonetheless, an early understanding of which bromodomain and acetylated lysine is essential for cellular function. Bromodomains are composed of ~110 amino acids that form a left-handed bundle of four α helices (αZ, αA, αB, αC) linked by the highly variable ZA and BC loop regions and constitute a deep, hydrophobic substrate binding pocket (36). Co-crystal structures of BET bromodomains and bound histone-derived peptides reveal that the acetyl-lysine side chain is anchored by a hydrogen bond formed with a conserved asparagine (e.g. Asn-140 in BRD4 BD1) located in the BC loop and also found in other bromodomains (37, 38). NMR spectroscopy of BRD4 BD2 associated to NF-κB-K310(ac) allowed the identification of key interacting amino acids including Asn-433, which makes a direct hydrogen bond with acetylated lysine (13). Additional amino acids in the ZA loop and in the αB and αC regions have been reported to be key for acetyl-lysine recognition (17). Several water molecules preventing further direct contacts are found at the bottom of the bromodomain pocket (39). X-ray structures solved in the presence of BET inhibitors such as JQ1 or I-BET762 show that these compounds effectively mimic the acetyl-lysine moiety (17, 18).

Although crystal structures can provide a static overview of the residues involved in interactions with substrates and small molecules, only a detailed mutational analysis of these residues can unravel their precise contributions to binding affinity. Up to now only a few such studies have been performed. The first reported BET mutants focused on the equivalent Tyr-139 and Tyr-432 or on Tyr-139 and Val-439 residues in BRD4 BD1 and BD2, respectively. These mutants have increased mobility and impaired interaction with acetylated chromatin in comparison to the wild-type form (40). Recently it was shown that mutating Asn-140 and Asn-433 in BRD4 BD1 and BD2, respectively, abolishes the binding to di-acetylated H4 peptides in a SPOT assay as well as in isothermal calorimetry, confirming the importance of the hydrogen bond formed by the highly conserved asparagine residue (4). Asn-140 and the neighboring Tyr-139 in BRD4 BD1 as well as the equivalent positions in BD2 are also important for the interaction with acetylated RelA (14). In the case of BRD2, surface plasmon resonance (SPR) reveals that additional BD1 residues including Tyr-113, Asn-156, and Asp-160 are essential for binding to a mono-acetylated H4 peptide (38). This was confirmed for Tyr-113 and its BD2 counterpart in living cells (41) and by immunoprecipitation (42). In murine BRDT, the Ile-114 mutant (43) and the triple mutant modified at positions Pro-50, Phe-51, and Val-55 (which correspond to Ile-112, Pro-48, Phe-49, and Val-53 in human BRDT) or at the equivalent positions in BD2 lose their binding to the H4 N-terminal tail (44). For BRD3, a detailed analysis of its interaction with acetylated GATA1 has been reported (45). Mutation of several hydrophobic residues has strong effects whereas, interestingly, mutation of the conserved Asn-116 residue, which forms the important hydrogen bond with the acetyl group of histone peptides, has little impact on binding, suggesting that, at least in this particular case, alternative recognition mechanisms are possible. Altogether, these examples indicate that disturbing individual interactions between BET bromodomains and their acetylated protein partners can have a significant impact on substrate binding, raising the question of whether these findings would be applicable to all members of the BET family and to interactions with small molecule inhibitors. The latter question can be relevant in the context of clinical use of BET inhibitors. For instance, following the approval of tyrosine kinase inhibitors, a number of resistance mechanisms originating from single point mutations of the targeted kinase have been identified in patients (46). Frequently, these mutations decrease the affinity of the drug for the kinase domain, whereas the catalytic activity is maintained. Furthermore, mutations affecting amino acids surrounding the binding site of the drug and reducing the availability of the target region toward the inhibitor without interfering with ATP binding have been described (47). Also, some mutations increase the affinity of the kinase for ATP, thus reducing the efficacy of the ATP-competitive inhibitors (48).

As the first BET inhibitors have just entered the clinic, no drug-induced resistance mutation has yet been described. Nonetheless, an early understanding of which bromodomain residues are likely to be involved in escape mechanisms from current BET small-molecule inhibitors may already guide the development of next-generation compounds.

The aim of this study was to investigate systematically with several complementary methods the structural determinants for the interaction of BRD4 with its natural ligands and inhibitors. To this end we evaluated the effect of mutations in the acetyl-lysine binding pocket of BRD4 BD1 on the recognition of various acetylated substrates and of the BET inhibitor JQ1. Fur-
thermore, we analyzed in detail the contribution to the binding of amino acid residues flanking the acetyl-lysines of the H4 N-terminal tail. Our results should serve to advance the current understanding of the mechanisms underlying selective chromatin recognition by bromodomains and may help to guide the future design of more potent and specific BET inhibitors.

**EXPERIMENTAL PROCEDURES**

**Plasmids**—The His-tagged human BRD4 BD1 expression construct pNIC28-Bsa4 (construct ID BRD4A-c002) and BRD4 BD2 expression construct pNIC28-Bsa4 (construct ID BRD4A-c011) have been described (17). For the photobleaching experiments we used full-length human BRD4 cDNA (RefSeq NM_058243.2) cloned into the pcDNA6.2/N-EmGFP-DEST plasmid (Invitrogen) used full-length human BRD4 cDNA (RefSeq NM_058243.2) have been described (17). For the photobleaching experiments we used full-length human BRD4 cDNA (RefSeq NM_058243.2) cloned into the pcDNA6.2/N-EmGFP-DEST plasmid (Invitrogen) used full-length human BRD4 cDNA (RefSeq NM_058243.2) have been described (17).

**Peptides**—Peptides corresponding to wild-type and mutant histone H4 (1–25), to histone H3 (1–21), and to RelA (301–320) were synthesized and purified at Biosyntan and AnaSpec with or without a C-terminal biotin tag. Their purities (>90%) and identities were verified by liquid chromatography mass spectrometry (LC-MS).

**Crystal Structures**—The crystal structures of BRD4 in complex with the acetylated H4 K5(ac)K8(ac) peptide and JQ1 (PDB codes 3UVW and 3MXF, respectively) were downloaded from the RCSB protein data bank and analyzed with the Maestro software (Schrödinger Release 2013-2: Maestro, Version 9.5, Schrödinger, LLC, New York, 2013) and with PyMOL (PyMol Molecular Graphics System, Version 1.3, Schrödinger, LLC).

**Site-directed Mutagenesis**—Point mutations were introduced into the pNIC28-Bsa4 and pTT5 constructs using the QuikChange II XL Site-directed Mutagenesis kit (Agilent Technologies) following the manufacturer’s instructions. Mutagenesis primers and their reverse sequence were synthesized by Eurofins MWG Operon and TIB MOLBIOL. The generated products were digested with DpnI for 1 h at 37 °C and transformed into XL10-Gold or XL1-Blue competent bacteria (Agilent Technologies). Plasmid DNA was purified from individual colonies as described above. The presence of the desired mutations was confirmed by DNA sequencing (SMB Services in Molecular Biology).

For the fluorescence recovery studies, mutant coding sequences were introduced into pcDNA6.2/N-EmGFP-BRD4 using the megaprimer PCR method (50) to amplify a BamHI/KpnI-flanked region (BD1) or KpnI/EcoRI-flanked region (BD2) of the wild-type expression plasmid using AccuPrime Pfx (Invitrogen). The expression plasmid and PCR products were digested with the appropriate restriction enzymes (New England Biolabs) followed by gel purification, dephosphorylation of the cut expression plasmid (Antarctic phosphatase, New England Biolabs), and ligation (T4 ligase, New England Biolabs) of the fragments to generate mutant GFP-tagged expression clones.

**Protein Expression and Purification**—BRD4 domains and mutants were expressed essentially as described (17) using One Shot BL21(DE3)pLysS bacteria stimulated with 0.5 mM isopropyl-β-D-thiogalactopyranoside (Sigma). Bacteria expressing His<sub>6</sub>-tagged proteins BRD4 BD1 or BD2 wild type were resuspended in 50 mM HEPES, pH 7.5 (Applichem), 500 mM NaCl (Sigma), 5% glycerol (Sigma), 5 mM imidazole (Sigma), 0.5 mM Tris(2-carboxyethyl)phosphine (Pierce), and EDTA-free Complete, and lysed using a Microfluidizer (Microfluidics). The proteins were then purified by affinity chromatography using nickel-nitrioltriacetic acid-agarose (Macherey-Nagel) or His-trap columns (GE Healthcare) followed by a size exclusion chromatography step using a Superdex S75 26/60 column (GE Healthcare). The mutated variants were purified by affinity chromatography using the nickel-nitrioltriacetic acid Fast Start Kit (Qiagen) following the instructions for purification under native conditions. A second purification step by size exclusion chromatography using a Superdex S75 16/60 column was then performed. The fractions were collected and monitored by SDS-polyacrylamide gel electrophoresis.

**LC-MS**—LC-MS analysis of purified proteins was performed in a nanoAcquity ultraperformance LC system coupled to a SYNAPT G2-S mass spectrometer with an electrospray ionization source (Waters). The protein samples were applied to Mass Prep C4, 2.1 × 5-mm trapping columns (Waters) using water containing 0.1% formic acid as mobile phase and then transferred using an acetonitrile gradient (20–80% in 6 min) in the presence of 0.1% formic acid and at a flow rate of 100 μl/min. Data were acquired over an m/z range of 450–2500 for 3.3 min.

**Thermal Shift Assay (TSA)**—In a typical TSA, 0.4 μg of BRD4 BD1 protein were mixed with 5× Sypro Orange (Molecular Probe) and adjusted to a final volume of 5 μl with 100 mM HEPES buffer, pH 7.5 (Applichem), and 150 mM NaCl (Sigma). For binding experiments, 1% DMSO (Sigma) or JQ1 in serial dilutions (0.14–119 μM, 3-fold) was added to the mixture. To protect samples from evaporation, they were overlaid with 1 μl of silicone oil DC200 (Sigma). Melting curves were recorded using a ThermoFluor system (Johnson and Johnson Pharmaceutical Research and Development) after heating the samples from 25 up to 95 °C while measuring the fluorescence intensity of the dye with the excitation and emission filters set to 465 and 590 nm, respectively. For data analysis, melting curves (fluorescence intensity changes at increasing temperatures) were fitted using a first derivative method (51) to determine the melting point \( T_m \) and the unfolding enthalpy \( \Delta H_u \) using the evaluation software provided by the manufacturer of the instrument. A series of thermal melting curves was collected in the presence of varying inhibitor concentrations. The heat capacity of protein unfolding (\( \Delta C_p_u \)) was assumed to be independent of the temperature and estimated from the size of the protein using the equation (52), \( \Delta C_p_u = -119 + 0.20 \times (907 + 93\#residues) \). The standard enthalpy of binding (\( \Delta H_{bind} \)) was calculated as fol-
Affinity Determinants of BRD4 Bromodomain Binding

Affinity determinants of BRD4 bromodomain binding with variable Hill slope, Y

response data from at least two independent experiments

\[
T_m = \frac{\Delta H^\circ - T_m(\text{DMSO})}{T_m(\text{DMSO})} + \Delta C_p \left(\frac{T_m(\text{DMSO})}{T_m(\text{DMSO})} + T_m(\text{DMSO})\right) \ln\left(\frac{T_m(\text{DMSO})}{T_m(\text{DMSO})}\right)
\]

The extrapolated standard free energy change \(\Delta G^\circ\) value in the function of the QJ1 concentration was fitted using the GraphPad Prism software and the following equation to obtain estimate \(K_D^*\) values:

\[
Y = -RT\ln\left(\frac{1}{K_D^*}\right) + \Delta S^* = \Delta G^\circ \times \Delta H^\circ
\]

Standard free energy of binding (\(\Delta G^\circ\)) and entropy (\(\Delta S^*\)) were calculated with the equations \(\Delta G^\circ = -RT\ln\left(1/K_D^*\right)\) and \(-\Delta S^* = \Delta G^\circ \times \Delta H^\circ\). To facilitate comparisons \(d\Delta G^\circ\) was also calculated: \(d\Delta G^\circ = \Delta G^\circ (\text{mt}) - \Delta G^\circ (\text{WT})\).

Time-resolved Fluorescence Resonance Energy Transfer (TR-FRET)—The TR-FRET binding assay used to measure the interaction of BRD4 with acetylated peptides was a modified version of a previously described protocol (18). The experiments were performed in 384-well black small volume microtiter plates (Greiner) in a buffer composed of 50 mM Hapes, pH 7.5 (Applichem), 50 mM NaCl (Sigma), 400 mM KF (Sigma), 0.5 mM CHAPS (Sigma), and 0.05% BSA (Sigma) in a final volume of 5–10 \(\mu\text{L} \ (n = 4)\). BRD4 (100 nM) protein domains were mixed with 200 nM concentrations of the biotin-labeled histone peptides and incubated for 30 min at room temperature. The protein-peptide complexes at equilibrium were then detected with 5 nM Eu\(^{3+}\) cryptate-conjugated streptavidin (CisBio) and 10 nM anti-His\(_6\)-XL665 (Cisbio). To analyze the binding of mutated histone peptides at different ionic strengths, streptavidin Eu\(^{3+}\) chelate (W1024, PerkinElmer Life Sciences) was used instead of cryptate as fluorescence donor, and KF was replaced by NaCl at concentrations of 20, 100, and 500 mM. After 3 h of further incubation at 4°C, the plates were measured in a PheraStar reader (BMG Labtech) using the homogeneous time-resolved fluorescence module (excitation, 337 nm with 10 flashes; emission, 620 and 665 nm). The 665-nm/620-nm ratios were converted to Delta F (Delta F (%) = (ratio sample - ratio background) \times 100/(ratio background)) to normalize experiments performed at different days and with different readers.

For competition assays 50 nM BRD4 BD1 and 500 nM BD2 protein were preincubated with serial dilutions of the unlabeled H4 (1–25) K5(ac)K8(ac)K12(ac)K16(ac) tetra-acetylated peptide (15 nM to 250 \(\mu\text{M}, 2\)-fold) or with JQ1 (0.61 nM to 10 \(\mu\text{M}, 2\)-fold) for 30 min at room temperature. The plates were then processed as described above. IC\(_{50}\) values were calculated by plotting the log [competitor/inhibitor] versus mean normalized response data from at least two independent experiments measured in triplicate and fitting it to a four-parameter equation with variable Hill slope, \(Y = \text{bottom} + (\text{top-bottom})/(1 + 10^{(\log IC_{50} - X) \times \text{Hill slope}})\), using the GraphPad Prism software. The IC\(_{50}\) values obtained under these experimental conditions can be expressed as \(K_D = K_D^*\) based on the Cheng-Prusoff equation (54): \(K_D = IC_{50}/(1 + [L]/K_D^*)\). Free energy of binding \(\Delta G\) and \(d\Delta G\) were calculated as described above.

SPR—SPR interaction analyses were conducted on Biacore 2000 and 2100 instruments (GE Healthcare) using standard buffers and protocols (Biacore\textsuperscript{TM} Assay Handbook). For peptide binding assays, BRD4 BD1 and BD2 (50 \(\mu\text{g/ml} \times 25 \text{ mm HEPES, pH 7}) were immobilized on 1000 M polycarboxylyl hydrogel sensor chips (Xantec) at densities varying between 2000 and 3000 RU using standard amine coupling methods based on ethyl(dimethylaminopropyl)carbodiimide/N-hydroxysuccinimide chemistry at densities varying between 2000 and 3000 RU. The analyte was an unlabeled tetra-acetylated H4 peptide flowed over the surface by injecting serial, 2-fold dilutions (0.16–20 \(\mu\text{M}) in running buffer (HBS-P+) over all surfaces at a flow rate of 30 \(\mu\text{l/min})

To evaluate the binding of the BRD4 BD1 mutants to histone tails in comparison to the wild type, a reverse set-up was used. Briefly, SA sensor chips (Biacore, GE Healthcare) were coated by injecting a 10 \(\mu\text{M}\) solution of the biotinylated tetra-acetylated H4 peptide used for TR-FRET assays at a flow rate of 10 \(\mu\text{l/min}\) until capture levels of 1100–1200 RU were achieved. To validate the surface, the wild-type protein was titrated on the chip at concentrations varying from 0.02 to 20 \(\mu\text{M}\), and the affinity parameters for the interaction were calculated as described above. After confirming that the \(K_D\) was in agreement with known values, all mutant and wild-type proteins were injected at a single concentration of 10 \(\mu\text{M}\) until equilibrium was established. Double referenced binding responses at equilibrium were used to calculate the surface activity or binding percentage: \% binding = (RUEq/Rmax) \times 100, where Rmax describes the binding capacity of the surface (\(M\), analyte/M, ligand \times RL, where RL is the immobilization level of the ligand (H4 peptide in this case)).

Fluorescence Polarization (FP)—The affinity of the BRD4 variants for JQ1 (3-((2R)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate) was estimated with an FP binding assay using the tetramethylrhodamine (TAMRA)-labeled JQ1 derivative 5-[[5-(((65S)-4-(4-chlorophenyl))-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetamido]pentyl]carbamoyl]-2-[(dimethylamino)-3-(dimethylaminio)-3-H-xanthene-9-yl]benzoate. To validate this fluorescent probe, its ability to displace the H4 peptide in the TR-FRET assay described above was assessed beforehand, and the \(K_D\) was found to be comparable with that of JQ1 (data not shown). For \(K_D\) determinations, 10 nM JQ1-TAMRA probe was incubated in 384-well small volume black microtiter plates with serial (1:2) dilutions of each BRD4 variant (0.61 nM to 10 \(\mu\text{M}\) in a buffer containing 10 mM HEPES, pH 7.5 (Applichem), 150 mM NaCl (Sigma), 0.005% Tween 20 (Sigma), and 0.5 mM Tris(2-carboxyethyl)phosphine (Calbiochem). After 30 min of incubation at room temperature, the plates were measured in a Tecan M1000 plate reader using its FP module and excitation/emission wavelengths of 530 and 570 nm, respectively. For \(K_D\) determinations the background-corrected polarization values were plotted against the concentrations of BRD4, and the data were fitted to a one-site binding equation: \(Y = B\text{max} \times X/(K_D + X)\), where \(Y\) is the specific binding, and \(B\text{max}\) is the maximal binding, using the GraphPad
Affinity Determinants of BRD4 Bromodomain Binding

Prism software. Free energy of binding $\Delta G$ was calculated as described above.

Fluorescence Recovery After Photobleaching (FRAP)—FRAP studies were performed using a protocol modified from previous work (17, 55). In brief, U2OS cells were reverse-transfected (Lipofectamine 2000, Invitrogen) with mammalian expression constructs encoding chimeric GFP-BRD4 (wild type or mutants). Where required, 1 $\mu$M JQ1 was added 1 h before imaging, which was carried out 24 h after transfection. The FRAP and imaging system consisted of a Zeiss LSM 710 scanhead (Zeiss GmbH) coupled to an inverted Zeiss Axio Observer, Z1 microscope equipped with a high numerical aperture (N.A. 1.3) 40x oil immersion objective (Zeiss GmbH) and a heated chamber set at 37 °C. FRAP and GFP fluorescence imaging were carried out with an argon-ion laser (488 nm) and with a photomultiplier tube detector set to detect fluorescence between 500–550 nm. A 13.4- $\mu$m$^2$ circular region (diameter of 70 pixels) of a GFP-positive nucleus was selected, and after 5 pre-scans, the region was bleached. A time-lapse series was then taken to record GFP recovery using 1% of the power used for bleaching with an interval time of ~0.25 s. The average intensity at each imaging time point was measured for three regions of interest: the bleached region (It), the total cell nucleus (Tt), and a random region outside of the bleached region (I). The total cell nucleus (Tt) and a random region outside of the bleached region (It) and a random region out in the bleached region were calculated for each timepoint.

The imaging data were obtained by importing the images into Microsoft Excel 2010, and the relative fluorescence signals were calculated using the 4-parameter nonlinear regression algorithm ($Y = \text{bottom} + \text{(top-bottom)}/(1 + 10^{(\log EC_{50} - X) \times \text{slope}}$) of the GraphPad Prism software (GraphPad Software).

RESULTS

Binding of BRD4 Bromodomains to Acetylated Peptides—To validate the experimental methods chosen for this study and to obtain first quantitative information on the interaction between the wild-type form of BRD4 bromodomains and acetylated peptides, we measured by TR-FRET the binding of purified BRD4 BD1 and BD2 to 14 peptides covering the H3 or H4 tails and containing one or several acetylated lysines. In addition, we tested the binding to one peptide derived from the acetylated region of RelA recently shown to interact with BRD4 (57).

The strongest binding signals were recorded for the interactions of BRD4 BD1 and BD2 with peptides bearing multiple acetylation sites, except for the H3K9(ac)K14(ac) and H4K5(ac)K12(ac) peptides. On the other hand, only low binding to the mono-acetylated H3 and H4 peptides was observed (Fig. 1A). No significant binding to RelA was observed, in contrast to recent studies, possibly due to the fact that different constructs were used (14). In several, but not all cases, better signals were detected for BD1 than for BD2. Based on the strong signal measured, the tetra-acetylated H4 peptide was selected for a more detailed study. It was used as a displacement probe in a competitive binding assay with the aim of comparing in detail the affinities of the wild-type and mutant BRD4 bromodomains for this peptide. The exquisite sensitivity of the TR-FRET technology allowed the concentrations of BRD4 BD1 and BD2 and of the peptide to be kept far below the affinity constants previously reported for the interaction (4, 39, 58). Under these conditions, the non-biotinylated tetra-acetylated H4 peptide should quantitatively displace the fluorescent probe in a dose-dependent fashion and with an IC$_{50}$ equivalent to the dissociation constant for the interaction (54). Using this experimental regime, dissociation constants of 4.8 and 30.6 $\mu$M were determined for BD1 and BD2, respectively (Fig. 1B and Table 1).

To gain more insight into the binding mode and further validate the results described above, we additionally analyzed BRD4 BD1 and BD2 interactions with the H4 tetra-acetylated peptide using the SPR method. The binding sensorgrams obtained for both BRD4 bromodomains indicated fast equilibrium kinetics for the interaction (Fig. 1, C and D), and the rates were often beyond the limits of what can be accurately measured by the reading instrument. Nevertheless, in the cases where the kinetic data could be reliably fitted to the Langmuir 1:1 model, the $K_D$ (kin) values derived from the kinetic parameters ($k_{on}$ and $k_{off}$) were similar to the equilibrium affinities (data not shown). Plotting the steady-state responses at different analyte concentrations (insets in
Fig. 1, C and D) yielded either full or partial binding saturation curves from which $K_D(\text{eq})$ values of 4.9 and 32.5 $\mu M$ were estimated for BD1 and BD2, respectively. These values were in excellent agreement with the affinity constants measured in the TR-FRET competition assay.

Influence of Amino Acids Neighboring Acetyl-lysines on H4 Recognition by BRD4 BD1—The TR-FRET assay described above was used to analyze in detail the binding of BRD4 BD1 to tetra-acetylated H4 mutated at different positions and in the presence of different salt concentrations (Fig. 2). Altogether, we found that the interaction of all H4 peptides with BRD4 BD1 was strongly reduced at 500 $\text{mM NaCl}$ concentration, compared with 20 and 100 $\text{mM}$. To determine if the amino acids of the H4 peptide located around the acetyl-lysine marks that do not directly interact with the bromodomain pocket nevertheless had an impact on the interaction, these residues were individually mutated to alanine, and the corresponding peptides were evaluated for BRD4 BD1 binding. Changing the residues that flank acetylated Lys-5 and Lys-8 to alanine led to significantly weaker BRD4 BD1 binding, especially at high ionic strengths, with the notable exception of the Gly-7 position (Fig. 2). In contrast, mutations at positions Arg-17, His-18, Arg-19, or Lys-20 or at position Ser-1 slightly strengthened the binding of BRD4 BD1 to the acetylated H4 peptide at low salt concentrations.

Specific Contributions of Selected Amino Acids of the BRD4 Bromodomain Pocket to Binding Affinity—We next examined the individual interactions of BRD4 BD1 with H4 K5(ac)K8(ac)
and with JQ1 in the available co-crystal structures (4, 17) in light of the conservation of the residues involved across the bromodomain family. This allowed selection of 10 amino acids whose mutations are likely to lead to measurable changes in binding affinity (Fig. 3). 4 of the 10 residues chosen are located in the ZA loop, namely the hydrophobic Trp-81 and Pro-82, which belong to the WPF shelf, and Leu-94 and Tyr-97, which face the binding pocket. Furthermore, we chose two residues in the αB helix, Asn-140, which forms the key hydrogen bond interaction but whose mutation in BRD3 intriguingly does not significantly affect binding to GATA1, and Tyr-139. Finally we selected the positively charged Asp-144 in the BC loop and Asp-145 and Ile-146 in the C helix, which enclose the hydrophobic shelf, and Met-149, which may affect the ZA channel and the hydrophobic shelf, although not directly part of the pocket. These 10 amino acids are entirely conserved across BD1 in the BET family and play distinct roles in the interaction with histone H4 and JQ1 (Fig. 3, A and B). They are also found in BD2, with the exception of Asp-144, Asp-145, and Ile-146, which are substituted for histidine, glutamic acid, and valine, respectively (Fig. 3 C). These residues were individually mutated to alanine, except Tyr-97 and Tyr-139, which were mutated to phenylalanine to keep the same overall conformation while eliminating the hydroxyl group that may undergo phosphorylation or be involved in hydrogen bonding.

Mutants of BRD4 BD1 were expressed and purified, and their expected mass and purity was confirmed by LC-MS analysis and SDS-PAGE, respectively (not shown). Differential scanning fluorimetry/TSA melting curves of mutated and wild-type BRD4 BD1 domains were comparable, indicating correct folding (not shown).

Binding of BRD4 BD1 mutants to H4 peptides was analyzed by TR-FRET as previously done for wild-type BD1 and BD2. Altogether, a reduction of the TR-FRET signals was observed for all mutants compared with the wild type (Fig. 4A). As for the wild-type BD1, the strongest binding was generally observed for the tetra-acetylated H4 peptide and the di-acetylated H4 peptide harboring acetylated Lys-5 and Lys-8. Conversely, very weak or no binding was seen for all mono-acetylated H4 peptides. Among the mutant proteins, P82A, Y139F, D144A, and I146A displayed the highest binding signals for the tetra-acetylated and most di-acetylated peptides. W81A, L94A, D145A, and M149A had significantly reduced binding activity, whereas Y97F and N140A showed the weakest interaction.

To confirm that the reduced TR-FRET signals at single concentrations of protein and peptide were an indicator of affinity decrease, we used the previously established TR-FRET competition assay for a precise quantification of the $K_D$ values. As expected, the P82A, Y139A, D144A, and I146A mutations had only a limited impact on the affinities in comparison to the wild-type protein. The affinities of D145A and L94A were more markedly reduced (5- and 8-fold, respectively), whereas for the W81A and M149A mutants the affinities were $<10$-fold that of the wild-type form (Fig. 4B and Table 1). The affinities of Y97F and N140A could not be quantified reliably due to the small dynamic window of the competition assay for these mutants.

### TABLE 1

| Assay type | Readout Parameter | BRD4 BD1 variant | WT | W81A | P82A | L94A | Y97F | Y139F | N140A | D144A | D145A | I146A |
|------------|-------------------|------------------|----|------|------|------|------|-------|-------|-------|-------|-------|
| | $K_D$ (μM) | | | | | | | | | | | |
| | $\Delta G$ (kJ mol$^{-1}$) | | | | | | | | | | | |
| | Binding (in %) | | | | | | | | | | | |
| | $t_1/2$ (s) | | | | | | | | | | | |

**Competition (in vitro)**

| Parameter | Readout | BRD4 BD1 variant | WT | W81A | P82A | L94A | Y97F | Y139F | N140A | D144A | D145A | I146A |
|-----------|---------|------------------|----|------|------|------|------|-------|-------|-------|-------|-------|
| | TR-FRET | | | | | | | | | | | |
| | SPR Binding (%) | | | | | | | | | | | |
| | FRAP $t_1/2$ (s) | | | | | | | | | | | |

**SPR surface activity normalized to wild type.**

**Measured with N140F mutant.**
The above-described results were further confirmed by SPR analysis of the interaction of immobilized H4 K5(ac)K8(ac)K12(ac)K16(ac) peptide with the purified BRD4 BD1 forms (Fig. 4C). We first validated the SPR surface by performing titrations of the wild-type BRD4 BD1 protein followed by steady state analysis of the sensorgrams (data not shown). The $K_d$ value of 2.4 $\mu M$ calculated from this experiment was consistent with the values obtained in previously described assays. The RU and % surface activity (=% binding) values obtained from the injection of a single concentration (near $K_d$) of wild-type or mutated bromodomain were, therefore, considered to be a $bona\ fide$ estimate of the affinity of the protein for the immobilized peptide. In these experiments all mutants showed a reduced interaction compared with the wild-type form. The effects were most pronounced for W81A, L94A, Y97F, and N140A for which the remaining binding was roughly 10% or less (Table 1).

**Impact of BRD4 BD1 Mutations on Nuclear Mobility**—To evaluate the effect of the mutations in a more physiological context, we performed FRAP experiments to assess the intracellular mobility of BRD4 BD1 mutants. Because this technique only allows detection of major differences in behavior, we focused on the mutants we found to be the most impaired in their recognition of acetylated histone H4 peptides in biochemical assays, namely those with mutated Trp-81, Tyr-97, Asn-140, and Met-149. We transfected human osteosarcoma U2OS cells with full-length, GFP-tagged BRD4 individually mutated to alanine or phenylalanine at these four BD1 locations as well as with BRD4 BD2 mutated at Asn-433 (which corresponds to Asn-140 in BD1) and with a double Asn-140/Asn-433 mutant. Successfully transfected cells were subjected to FRAP analysis, and the half-recovery times of wild-type and mutant BRD4 bromodomains were determined. The Asn-140 and Asn-433 residues were modified to either alanine or phenylalanine residues with essentially the same results. As the transfection efficiency was better for the phenylalanine mutants, only these data are shown. Cells transfected with GFP-BRD4 wild type with or without treatment of the BET inhibitor JQ1 were used as references (Fig. 5A). All BRD4 BD1 and BD2 mutants showed a quicker recovery of fluorescence intensity than the wild-type protein in the cell nuclei, indicative of displaced and freely diffusing proteins. For all mutants, the enhanced half-fluorescence recovery was comparable to that seen for BRD4 wild-type in JQ1-treated cells (Fig. 5B and Table 1).

**Affinity Determinants for BRD4 Recognition by the Small Molecule Inhibitor JQ1**—Although JQ1 efficiently mimics the acetyl-lysine group and occupies the same space in the BRD4 BD1 pocket (17), it does not make exactly the same interactions with the protein as do the acetylated histones (Fig. 3, A and B). We, therefore, decided to compare in detail the respective interactions of JQ1 and the tetra-acetylated H4 peptide with the different BD1 point mutants we generated. An important point we wished to investigate was whether the reduction of BRD4 BD1 mutant interaction with histone peptides translated into a quantitative loss of inhibitor binding. To this end a TAMRA-labeled JQ1 derivative was titrated with increasing concentrations of the mutants, and FP of the probe was used as indicator for complex formation (Fig. 6A). The results summarized in Table 2 indicate that JQ1 binding to the Y139F and D145A mutants was not significantly different compared with wild-type BRD4 BD1. The strongest effects were observed for P82A, Y97F, N140A, I146A, and M149A and especially for the W81A mutant.

To test whether the results obtained using a JQ1 derivative recapitulated the interactions of the parent compound with BRD4, we analyzed the effects of JQ1 on unfolding thermodynamics of the BRD4 BD1 mutants using TSA. To this end we recorded melting curves of the wild-type and of each mutant at increasing ligand concentrations. As previously reported (17), JQ1 binding resulted in thermal stabilization of BRD4 BD1, and raising ligand concentrations increased the protein thermal stability (not shown). Analysis of the melting points of the mutants in the presence of 100 $\mu M$ JQ1 revealed that the W81A, Y97F, N140A, and M149A forms were the least stabilized by JQ1, whereas the mutants P82A, L94A, and I146A showed a moderate stabilization profile (Table 2). Conversely, JQ1 stabilized the Y139F, D144A, and D145A mutants as strongly as wild-type BD1. The $\Delta T_m$ values at 100 $\mu M$ JQ1 were in good agreement with the affinities of the mutants for JQ1 in the FP assay (Table 2). Encouraged by these results, we used the $\Delta T_m$ and $\Delta H_u$ parameters obtained from the experiments to estimate the binding enthalpy $\Delta H_u$ and evaluate the impact of JQ1 on the protein stability change $\Delta \Delta G'_u$ (Fig. 6B). Using the appropriate parameters, we calculated the $\Delta \Delta G'_u$ values and compared them with the $K_d$ values obtained from the SPR analysis (Table 2). The results show a linear correlation between the two parameters, indicating that JQ1 binding contributes to the unfolding of BRD4 BD1 mutants as well as to the wild-type protein.
equations and making assumptions discussed elsewhere (52, 53, 59), we also derived $K_D$ values for the interaction of JQ1 with the different mutants. The results of these studies are summarized in Table 2. The calculated standard binding enthalpy $\Delta H^o_b$ of BRD4 BD1 wild type to JQ1 of $-13.8 \text{ kJ mol}^{-1}$ was in the same range as the $-8.42 \text{ kcal mol}^{-1}$ previously measured by isothermal calorimetry (17). Loss of stabilization by JQ1 translated into loss of relative free energy of binding $\Delta G^o$, which, however, remained negative along with the binding enthalpy $\Delta H^o_b$ and entropy changes $T\Delta S^o$ (Table 2). As anticipated from the $\Delta T_{m}^o$ values, the thermodynamic data obtained from the TSA experiments supported the affinity ranking of the mutants obtained using the FP assay.

The effects of BD1 mutations on JQ1 binding are also expected to influence the inhibitory activity of the compound. We, therefore, determined the interaction of JQ1 with each
**FIGURE 4.** Binding of BRD4 BD1 mutants to acetylated peptides. A, TR-FRET delta F (%) quantification (±S.D.) of BRD4 BD1 (wild-type and mutants, 50 nM each) binding to different acetylated H4 histone tails (200 nM each). B, determination of BRD4 BD1 affinity to H4 K5(ac)K8(ac)K12(ac)K16(ac) with a TR-FRET homogeneous competition assay. 200 nM biotinylated H4 peptide and 50 nM protein were titrated with unlabeled H4 peptide at the concentrations indicated. Delta F values were plotted against the concentrations of unlabeled peptide (competitor). The fitting of the normalized data (not shown) to the four-parameter equation described under “Experimental Procedures” (colored lines) served to calculate the $K_D$ values indicated in Table 1. All data represent the mean values of at least two experiments with multiple replicates each.

**FIGURE 5.** Effect of bromodomain mutation on BRD4 dissociation from chromatin by FRAP evaluation. A, nuclei of U2OS cells transfected with GFP-tagged wild-type BRD4, bromodomain mutants or with wild-type BRD4 and treated with JQ1. The bleached area is indicated by a red circle. B, time dependence of fluorescent recovery in the bleached area for wild-type, mutant, or treated cells. Curves represent the means at each time point of at least 12 cells in each group.
Affinity Determinants of BRD4 Bromodomain Binding

FIGURE 6. Determination of BRD4 BD1 wild-type and mutant affinities for the small molecule inhibitor JQ1 in vitro and in cells. A, FP analysis of BRD4 BD1 wild-type and mutant binding to TAMRA-labeled JQ1. The TAMRA-labeled JQ1 tracer (10 nm) was titrated with increasing concentrations of protein as indicated, and blank-subtracted fluorescence polarization values were plotted versus protein concentration. The lines show the fit of the data to a single-site equilibrium binding equation described under “Experimental Procedures.” The $K_d$ values obtained from these fits are indicated in Table 2. B, TSA analysis of BRD4 BD1 wild-type and mutant binding to JQ1. The compound-induced changes in free energy of unfolding ($\Delta G^0$) were plotted versus JQ1 concentration, and the data were fitted to the equation described under “Experimental Procedures” (colored lines). These fits served to calculate the $K_d$ values shown in Table 2. C, TR-FRET competition assay. 200 nm biotinylated H4 peptide and 50 nm wild-type or mutant proteins were titrated with JQ1 at the concentrations indicated in the graph. Plots of the Delta F data versus JQ1 concentration were fitted to the four-parameter equation described under “Experimental Procedures” (colored lines) to calculate the $K_d$ values indicated in Table 2. D, cellular stabilization of BRD4 wild-type and mutants by JQ1. HEK293 cells expressing wild-type and mutant variants of BRD4 BD1 were incubated with JQ1 and tested following the protocol given under “Experimental Procedures.” Fitting the plots of TR-FRET ratio at increasing JQ1 concentrations was used to calculate the $EC_{50}$ values for protein stabilization.

puriﬁed mutant in the TR-FRET competition assay using biotinylated H4 tetra-acetylated peptide as tracer (Fig. 6C). We calculated the $K_d$ of JQ1 for those mutants with sufﬁcient afﬁnity to allow an appropriate assay window. W81A, Y97F, N140A, and M149A were, therefore, excluded from this analysis. The results are summarized in Table 2. Surprisingly, the most dramatic effect was seen with D145A, where a 6-fold increase of inhibitory activity was observed.

Impact of BRD4 BD1 Mutations on JQ1-Mediated Protein Stability in Cells—To assess the relevance of our ﬁndings with JQ1 in a cellular context, we built on the fact that ligand-induced stabilization of proteins has recently been shown to take place in living cells (60) and hypothesized that small molecule inhibitors of BRD4 bromodomains can increase the half-life of the targeted protein in cells. To this end we developed a novel assay system that detects changes in BRD4 BD1 protein levels in cell lysates by TR-FRET. As shown in Fig. 6D, incubation of cells expressing BRD4 BD1 with JQ1 led to a dose-dependent and saturable increase of the TR-FRET signals, indicative of increased protein levels. The $EC_{50}$ value measured for stabilization of wild-type BRD4 was 0.1 $\mu$M, in concordance with the $IC_{50}$ determined in the biochemical TR-FRET competition experiment (Table 2). In line with the biochemical data, all mutated BRD4 variants that were least recognized by JQ1, namely Trp-81, Pro-82, Tyr-97, Asn-140, and Met-149, showed a much higher $EC_{50}$ in the cellular stabilization assay (from 7-fold to >100-fold), indicative of a reduced recognition by JQ1 inside cells. The effects were most pronounced for the N140A and especially the M149A mutants.

DISCUSSION

The BET BRD4 protein plays a major role in cancer development as a reader of acetylated histones, and ﬁrst clinical studies with inhibitors targeting BET bromodomains have already been initiated. A detailed understanding of the bromodomain residues engaged in acetylated lysine and inhibitor binding will be essential for the identiﬁcation of compounds with an improved pharmacological proﬁle. Mutations in epigenome regulators, including histone mark readers, have already been described in several cancer types, and their efﬁcient targeting may be the scope of next generation inhibitors (61).

Using different biophysical and biochemical methods, we ﬁrst compared the binding proﬁles of BRD4 BD1 and BD2 to different acetylated H4 and H3 peptides and thereafter analyzed the contribution of individual BD1 amino acids. The results of the binding measurements allowed us to identify the tetra-acetylated peptide H4 K5(ac)K8(ac)K12(ac)K16(ac) and the di-acetylated peptide H4 K5(ac)K8(ac) as the best binding partners of BRD4 BD1. Furthermore, the fast kinetics of the interactions between BRD4 BD1 or BD2 and the tetra-acetylated H4 were shown for the ﬁrst time. BRD4 BD1 had a >6-fold higher afﬁnity for the tetra-acetylated H4 peptide than
Affinity and stabilization thermodynamics of BRD4 BD1 interaction with JQ1

| BRD4 BD1 variant | WT | W81A | P82A | L94A | Y97F | Y139F | N140A | D144A | D145A | I146A | M149A |
|------------------|----|------|------|------|------|-------|-------|-------|-------|-------|-------|
| Mean values of the affinity and thermodynamics parameters derived from FP, TSA, and TR-FRET measurements (± S.D.) are listed. Values not shown either could not be interpreted (NI) in the TR-FRET competition experiments or were not determined (ND) in the protein stabilization studies. |
| **Parameter** | **Binding (K_D)** | **TSA** | **TR-FRET** | **Protein stabilization** |
| | | | | | | | | | | | |
| | FP | N | N | N | N | N | N | N | N | N | N |
| | TSA | N | N | N | N | N | N | N | N | N | N |
| | TR-FRET | N | N | N | N | N | N | N | N | N | N |
| | Protein stabilization | N | N | N | N | N | N | N | N | N | N |
| | Measured with 100 µM JQ1 | N | N | N | N | N | N | N | N | N | N |

**Table 2**

Affinity Determinants of BRD4 Bromodomain Binding

The mutated histone peptide in low salt concentrations suggesting an indirect underlying cause such as higher solubility of the mutated histone peptide in low salt concentrations compared with the non-mutated peptide form.
Affinity Determinants of BRD4 Bromodomain Binding

FIGURE 7. Three-dimensional affinity map of BRD4 interactions with H4 tail and JQ1. Residues investigated in this study are highlighted in the crystal structures of BRD4 complexed with H4K5(ac)K8(ac) (A) and JQ1 (B). The colors represent the loss of absolute free energy of binding (dΔG) associated with the individual mutations. dΔG values were calculated by subtracting free energy of binding of the wild-type from the mutants. Non-mutated BRD4 regions are shown in gray, the H4K5(ac)K8(ac) peptide is shown in green, and JQ1 is in magenta. The dΔG values were calculated from the TR-FRET experiment (panel A) and the dΔG* values from the TSA experiment (panel B). n.i., not interpreted.

As exemplified in the case of tyrosine kinase inhibitors, point mutations in protein regions targeted by drugs are a frequent escape mechanism observed in treated cancer patients. No such example exists for BRD4, but clinical studies are still in their early phase. We, therefore, studied in detail the role of individual BRD4 bromodomain residues in the interaction with acetylated histones and small molecule inhibitors. The crystal structures of BRD4 BD1 bound to the acetylated H4 peptide or to different inhibitors show the compounds to mimic acetyl-lysine but also to engage in somewhat different interactions. Based on these observations we selected 10 amino acids belonging to the binding pocket for site-directed mutagenesis and thorough analysis of the corresponding mutated BRD BD1 region.

The affinity of these mutants for H4 and JQ1 was compared with the wild-type form using the free energy of binding calculated from the competitive TR-FRET and TSA experiments. Altogether, the results allowed us to draw a three-dimensional affinity map of the BRD4 pocket engaged in interactions with histone H4 (Fig. 7A) or with JQ1 (Fig. 7B). The loss of absolute free energy of binding of each mutant compared with wild-type BD4 BD1 was color-coded depending on the difference measured. From these results, three different groups of mutations can be identified.

We first focused on mutants where important losses of histone and JQ1 binding were noted. The prime example is Asn-140, for which a strong reduction of binding properties was expected based on previous studies due to the formation of an essential hydrogen bond with the carbonyl group of the acetyl mark and with the 3-methyl-1,2,4-triazole ring of JQ1 (63, 64). Indeed, the Asn-140 position has already been shown to be essential for the reading function of many but not all bromodomains (4). For instance, the corresponding mutation in BRD3 BD1 has no impact on binding to GATA1 (45), suggesting that the interaction between a bromodomain and its acetylated partner may in some instances follow different rules. The Tyr-97 mutant also had severely impaired binding properties. Cocystal structures indicate that Tyr-97 interacts indirectly by hydrogen bonding through a water molecule with the acetylated lysine (39) and also with JQ1 (17). The effects we observed are in line with comparable mutations in BRD2 and BRD3 showing Tyr-97 to be critical for binding to mono-acetylated H4 (38) and to GATA1 (45), respectively. Interestingly, molecular dynamic simulations (65) showed both Asn-140 and Tyr-97 as well as Tyr-139 to be located in a flexible region (see also Fig. 7A) allowing rotation between an inward and an outward position, which may affect recognition of the acetyl-lysine binding site. Two other residues were essential for peptide and inhibitor binding, namely the hydrophobic amino acids Trp-81 and Met-149. Both positions are known to be essential in BRD3 BD1 for its interaction with the GATA1 peptide (45). Interestingly, an alanine residue is found at the Trp-81 position in the BRD7 bromodomain, which has only low binding affinity for acetylated peptides (66). Trp-81 together with Pro-82 and Phe-83 form the hydrophobic WPF shelf (6, 67). In our study the hydrophobic interaction between JQ1 and Trp-81 was as important as the hydrogen bonds formed with Tyr-97 and Asn-140. The effects were less pronounced for the Met-149 mutation but still very marked. Importantly Trp-81 and Met-149 together with Ile-146 form the hallmark signature of the BET bromodomain group and are predictive of high drug-ability (6). In the BET family, the position corresponding to Met-149 is conserved, whereas in the BAZ family it is replaced by the small amino acids alanine or cysteine, which allow the tryptophan to move close to residue 149, thereby removing the ZA channel and hydrophobic shelf (6). Altogether these data show that Trp-81, Tyr-97, Asn-140, and Met-149 are key amino acids for histone and JQ1 binding, which is why we additionally analyzed them in a cellular context. Using FRAP, we observed an impaired chromatin recognition for all of the corresponding mutants. In a cellular stabilization assay performed in the presence of JQ1, reduced binding was also observed. Altogether these data demonstrate the bromodomain pocket of these mutants to lack essential residues for acetyl-lysine and inhibitor binding. These four residues can, therefore, be grouped based on their key role in the interaction with both acetylated histone H4 and JQ1.

A second group with a mixed profile was identified. It includes residues Pro-82, Ile-146, Leu-94, and Asp-145. The
P82A mutation had little effect on H4 peptide binding but led to affinity loss toward JQ1 (Fig. 7). These results show that the interactions of Pro-82 with H4 that include two indirect hydrogen bonds with the acetylation marks are rather weak, whereas the interactions with JQ1 are strong due to hydrophobic forces engaged with the thiophene group of the compound. The I146A mutation showed a strong loss of affinity for H4, whereas binding to JQ1 was only partially affected. Interestingly, the nature of this gatekeeper residue varies outside of the BET family, suggesting this position to be essential for the diversity of bromodomain functions. In BRDT, introducing a large, bulky residue at this position entirely suppresses reorganization of hyper-acetylated chromatin (43). The L94A mutation led to a strong loss of affinity to the histone H4 tail comparable to that seen for members of the first group, whereas binding to JQ1 was only weakly affected. Concerning Asp-145, the affinity loss calculated for the mutant indicates that this residue forms medium strength hydrogen bonds directed toward the H4 backbone but does not interact with the nearby chlorophenyl group of JQ1. Competitive experiments involving JQ1 and tetra-acetylated H4 were performed with this mixed profile group. They showed that JQ1 was a better inhibitor of the interaction of BRD4 with the H4 peptide when Leu-94 and Asp-145 were mutated to alanine, whereas it showed similar inhibition for I146A or a slightly decreased one for P82A in comparison to the wild-type protein.

The third group we could define includes Asp-144 and Tyr-139. For both these mutated residues, the JQ1 and histone binding affinities were only slightly altered in comparison to the wild-type protein, indicating a marginal role in binding of either partner. Interestingly, the BD1 residue Asp-144 is replaced by histidine in BD2, which can affect both the overall structure and the local charge and possibly account for the different function of these bromodomains.

Overall our results provide a deeper understanding of the role of individual amino acids in histone and inhibitor recognition. They identify the key amino acids that inhibitors like JQ1 need to address for efficient inhibition of BRD4 and also reveal that residues with a mixed profile between loss of binding to histone and to JQ1 exist. The data also show that different kinds of interactions take place, suggesting that resistance mutations compatible with BRD4 function are possible. Future analysis of clinical samples will show whether such mutations occur in patients treated with BET inhibitors.

Acknowledgments—We thank Nicole Dittmar, Alexandra Einfeldt, Marcel Geyer, Marina Isernhagen, Anne Mattstedt, and Sabine Schnabel for excellent technical support. We are grateful to Matthias Busemann, Clara Christ, Simon Holton, Tatsuo Sugawara, Jörg Weiske, and Kathy Gelato for helpful scientific discussions.

REFERENCES

1. Berger, S. L. (2007) The complex language of chromatin regulation during transcription. Nature 447, 407–412
2. Bannister, A. J., and Kouzarides, T. (2011) Regulation of chromatin by histone modifications. Cell Res. 21, 381–395
3. Zeng, L., and Zhou, M. M. (2002) Bromodomain. An acetyl-lysine binding domain. FEBS Lett. 513, 124–128
4. Filippakopoulos, P., Picaud, S., Mangos, M., Keates, T., Lambert, J. P., Barsyte-Lovejoy, D., Felletar, I., Volkmer, R., Müller, S., Pawson, T., Gintragas, A. C., Arrowsmith, C. H., and Knapp, S. (2012) Histone recognition and large-scale structural analysis of the human bromodomain family. Cell 149, 214–231
5. Florence, B., and Faller, D. V. (2001) You bet-cha. A novel family of transcriptional regulators. Front Biosci. 6, D1008–D1018
6. Vidler, L. R., Brown, N., Knapp, S., and Høelde, S. (2012) Druggability analysis and structural classification of bromodomain acetyl-lysine binding sites. J. Med. Chem. 55, 7346–7359
7. Wang, R., Li, Q., Helfer, C. M., Jiao, J., and You, J. (2012) The bromodomain protein Brd4 associated with acetylated chromatin is important for maintenance of higher-order chromatin structure. J. Biol. Chem. 287, 10738–10752
8. Jang, M. K., Mochizuki, K., Zhou, M., Jeong, H. S., Brady, J. N., and Ozato, K. (2005) The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription. Mol. Cell 19, 523–533
9. Schröder, S., Cho, S., Zeng, L., Zhang, Q., Kaehlcke, K., Mak, L., Lau, J., Biegrove, D., Schnöller, M., Verdin, E., Zhou, M. M., and Ott, M. (2012) Two-pronged binding with bromodomain-containing protein 4 liberates positive transcription elongation factor b from inactive ribonucleoprotein complexes. J. Biol. Chem. 287, 1090–1099
10. Yang, Z., He, N., and Zhou, Q. (2008) Brd4 recruits P-TEFb to chromosomes at late mitosis to promote G1 gene expression and cell cycle progression. Mol. Cell. Biol. 28, 967–976
11. Chiang, C. M. (2009) Brd4 engagement from chromatin targeting to transcriptional regulation. Selective contact with acetylated histone H3 and H4. F1000 Biol. Rep. 1, 98
12. Zhang, W., Prakash, C., Sum, C., Gong, Y., Li, Y., Kwok, J. J., Thiessen, N., Pettersson, S., Jones, S. J., Knapp, S., Yang, H., and Chin, K. C. (2012) Bromodomain-containing protein 4 (BRD4) regulates RNA polymerase II serine 2 phosphorylation in human CD4+ T cells. J. Biol. Chem. 287, 43137–43155
13. Zhang, G., Liu, R., Zhang, Y., Plotnikov, A. N., Zhang, W., Zeng, L., Rusinova, E., Gerona-Navarro, G., Moshkina, N., Joshua, J., Chuang, P. Y., Ohlmeyer, M., He, J. C., and Zou, M. M. (2012) Down-regulation of NF-kB transcriptional activity in HIV-associated kidney disease by BRD4 inhibition. J. Biol. Chem. 287, 28840–28851
14. Zou, Z., Huang, B., Wu, X., Zhang, H., Qi, J., Bradner, J., Nair, S., and Chen, L. F. (2013) Brd4 maintains constitutively active NF-kB in cancer cells by binding to acetylated RelA. Oncogene 10.1038/onc.2013.179
15. Rahman, S., Sowa, M. E., Ottinger, M., Smith, J. A., Shi, Y., Harper, J. W., and Howley, P. M. (2011) The Brd4 extraterminal domain confers transcription activation independent of pTEFb by recruiting multiple protein partners, including NSD3. Mol. Cell. Biol. 31, 2641–2652
16. Oliver, S. S., and Denu, J. M. (2011) Disrupting the reader of histone language. Angew Chem. Int. Ed. Engl. 50, 5801–5803
17. Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., Philpott, M., Munro, S., McKeown, M. R., Wang, Y., Christie, A. L., West, N., Cameron, M. J., Schwartz, B., Heightman, T. D., La Thangue, N., French, C. A., Wiest, O., Kung, A. L., Knapp, S., and Bradner, J. E. (2010) Selective inhibition of BET bromodomains. Nature 468, 1067–1073
18. Nicodeme, E., Jeffrey, K. L., Schaefer, U., Beinke, S., Dewell, S., Chung, C. W., Chandwani, R., Marazzi, I., Wilson, P., Coste, H., White, J., Kirillovsky, J., Rice, C. M., Lora, J. M., Prinjha, R. K., Lee, K., and Tarakhovsky, A. (2010) Suppression of inflammation by a synthetic histone mimic. Nature 468, 1119–1123
19. Dawson, M. A., Prinjha, R. K., Dittman, T., Giotopoulos, G., Bantscheff, M., Chan, W. I., Robson, S. C., Chung, C. W., Hofp, C., Savitski, M. M., Huthmacher, C., Gudjín, E., Lugo, D., Beinke, S., Chapman, T. D., Roberts, E. J., Soden, P. E., Auger, K. R., Mirguet, O., Doehner, K., Delwel, R., Burnett, A. K., Jeffrey, P., Drewes, G., Lee, K., Huntly, B. J., and Kouzarides, T. (2011) Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 478, 529–533
20. Delmore, J. E., Issa, G. C., Lemieux, M. E., Rahi, P. B., Shi, J., Jacobs, H. M., Kastritis, E., Gilpatrick, T., Paranil, R. M., Qi, J., Chesi, M., Schinzel, A. C.,
Affinity Determinants of BRD4 Bromodomain Binding

McKeown, M. R., Hefferman, T. P., Yakoc, C. R., Bergsagel, P. L., Ghobrial, I. M., Richardson, P. G., Young, R. A., Hahn, W. C., Anderson, K. C., Kung, A. L., Bradner, J. E., and Mitsiades, C. S. (2011) BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146, 904–917

Mertz, J. A., Conery, A. R., Bryant, B. M., Sandey, P., Balasubramanian, S., Mele, D. A., Bergeron, L., and Sims, R. J., 3rd. (2011) Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc. Natl. Acad. Sci. U.S.A. 108, 16669–16674

Lovén, J., Hoke, H. A., Lin, C. Y., Lau, A., Orlando, D. A., Yakoc, C. R., Bradner, J. E., Lee, T. I., and Young, R. A. (2013) Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 153, 320–334

Wu, S. Y., Lee, A. Y., Lai, H. T., Zhang, H., and Chiang, C. M. (2013) Phospho switch triggers BRD4 chromatin binding and activator recruitment for gene-specific targeting. Mol. Cell 49, 843–857

French, C. A., Miyoshi, I., Aster, J. C., Kubonishi, I., Kroll, T. G., Dal Cin, P., Vargas, S. O., Perez-Atayde, A. R., and Fletcher, J. A. (2001) BRD4 bromodomain gene rearrangement in aggressive carcinoma with translocation t(15;19). Am. J. Pathol. 159, 1967–1977

French, C. A., Miyoshi, I., Kubonishi, I., Grier, H. E., Perez-Atayde, A. R., and Fletcher, J. A. (2003) BRD4-NUT fusion oncogene. A novel mechanism in aggressive carcinoma. Cancer Res. 63, 304–307

French, C. A. (2013) The importance of diagnosing NUT midline carcinoma. Head Neck Pathol. 7, 11–16

Herrmann, H., Blatt, K., Shi, J., Gleixner, K. V., Cermelj-Reiterer, S., Müller, L., Yakoc, C. R., Serr, W. R., Horny, H. P., Bradner, J. E., Zuber, J., and Valent, P. (2012) Small-molecule inhibition of BRD4 as a new potential approach to eliminate leukemic stem and progenitor cells in acute myeloid leukemia AML. Oncotarget 3, 1588–1599

Da Costa, D., Agathanggelou, A., Perry, T., Weston, V., Petermann, E., Zlatanov, A., Oldreive, C., Wei, W., Stewart, G., Longman, J., Smith, E., Kearns, P., Knapp, S., and Stankovic, T. (2013) BET inhibition as a single or combined therapeutic approach in primary paediatric B-precursor acute lymphoblastic leukaemia. Blood Cancer J. 3, e162

Zuber, J., Shi, J., Wang, E., Rappaport, A. R., Herrmann, H., Sison, E. A., Magoon, D., Qi, J., Blatt, K., Wunderlich, M., Taylor, M. J., Johns, C., Chicas, A., Mulloy, J. C., Ogan, S. C., Brown, P., Valent, P., Bradner, J. E., Lowe, S. W., and Yakoc, C. R. (2011) RNAi screen identifies BRD4 as a therapeutic target in acute myeloid leukemia. Nature 478, 524–528

Puissant, A., Frumm, S. M., Alexe, G., Bassil, C. F., Qi, J., Chantry, Y. H., Nekritz, E. A., Zeid, R., Gustafson, W. C., Greninger, P., Garnett, M. J., McDermott, U., Benes, C. H., Kung, A. L., Weiss, W. A., Bradner, J. E., and Stegmaier, K. (2013) Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov. 3, 308–323

Wyce, A., Ganji, G., Smithethan, K. N., Chung, C. W., Korenchuk, S., Bai, Y., Barbash, O., Le, B., Craggs, P. D., McCabe, M. T., Knapp, S., and McKeown, M. R. (2000) The structural basis for gene-specific targeting. Mol. Cell 5, 10831–10841

Shirouzu, M., Padmanabhan, B., Yokoyama, S., Itou, S., and Yoshida, M. (2004) Real-time imaging of histone H4K12-specific acetylation determines the modes of action of histone deacetylase and bromodomain inhibitors. Chem. Biol. 11, 495–507

Kanno, T., Kanno, Y., Siegel, R. M., Jang, M. K., Lenardo, M. J., and Ozato, K. (2004) Selective recognition of acetylated histones by bromodomain proteins visualized in living cells. Mol. Cell 13, 33–43

Morenière, J., Rousseaux, S., Steuwerl, U., Soler-López, M., Curtet, S., Vitte, A. L., Govin, J., Gaucher, J., Sado, L., J. D., Krigsveld, J., Khochbin, S., Müller, C. W., and Petosa, C. (2009) Cooperative binding of two acetylation marks on a histone tail by a single bromodomain. Nature 461, 661–668

Pivot-Pajot, C., Caron, C., Govin, J., Vian, A., Rousseaux, S., and Khochbin, S. (2003) Acetylation-dependent chromatin reorganization by BRDT, a testis-specific bromodomain-containing protein. Mol. Cell Biol. 23, 5534–5565

Gamsjaeger, R., Webb, S. R., Lamonica, J. M., Billin, A., Blobel, G. A., and Mackay, J. P. (2011) Structural basis and specificity of acetylated transcription factor GATA1 recognition by BET family bromodomain protein Brd3. Mol. Cell Biol. 31, 2632–2640

Sierra, J. R., Cepero, V., and Giordano, S. (2010) Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy. Mol. Cancer 9, 75

Zhang, J., Yang, P. L., and Gray, N. S. (2009) Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer 9, 28–39

Yun, C. H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K. M., Meyerson, M., and Eck, M. J. (2008) The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc. Natl. Acad. Sci. U.S.A. 105, 2070–2075

Durocher, Y., Perret, S., and Kamen, A. (2002) High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells. Nucleic Acids Res. 30, E9

Barik, S. (1993) Site-directed mutagenesis by double polymerase chain reaction. Megaprimer method. Methods Mol. Biol. 15, 277–286

Brandts, J. F., and Lin, L. N. (1990) Study of strong to ultratight protein interactions using differential scanning calorimetry. Biochemistry 29, 6927–6940

Myers, K. J., Pace, C. N., and Scholtz, J. M. (1995) Denaturant m values and heat capacity changes. Relation to changes in accessible surface areas of protein unfolding. Protein Sci. 4, 2138–2148

Rayton, C. J., and Hellinga, H. W. (2010) Thermodynamic analysis of ligand-induced changes in protein thermal unfolding applied to high-throughput determination of ligand affinities with extrinsic fluorescent dyes. Biochemistry 49, 10831–10841

Cheng, Y., and Prusoff, W. H. (1973) Relationship between the inhibition constant (K) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 22, 3099–3108

Vollmuth, F., Blankenfeldt, W., and Geyer, M. (2009) Structures of the dual bromodomain protein Brd4 binds to acetylated chromatin during interphase and mitosis. Proc. Natl. Acad. Sci. U.S.A. 100, 8758–8763

Dey, A., Chitsaz, F., Abbasi, A., Misteli, T., and Ozato, K. (2003) The double bromodomain protein Brd4 binds to acetylated chromatin during interphase and mitosis. Proc. Natl. Acad. Sci. U.S.A. 100, 8758–8763

Umehara, T., Nakamura, Y., Jang, M. K., Nakano, K., Tanaka, A., Ozato, K., Padmanabhan, B., and Yokoyama, S. (2010) Structural basis for acetylated histone H4 recognition by the human BRD2 bromodomain. J. Biol. Chem. 285, 7610–7618

Phair, R. D., Gorski, S. A., and Misteli, T. (2004) Measurement of dynamic...
protein binding to chromatin in vivo, using photobleaching microscopy. *Methods Enzymol.* **375**, 393–414

57. Huang, B., Yang, X. D., Zhou, M. M., Ozato, K., and Chen, L. F. (2009) Brd4 coactivates transcriptional activation of NF-κB via specific binding to acetylated RelA. *Mol. Cell. Biol.* **29**, 1375–1387

58. Chung, C. W., and Witherington, J. (2011) Progress in the discovery of small-molecule inhibitors of bromodomain-histone interactions. *J. Biol. Screen* **16**, 1170–1185

59. Matulis, D., Kranz, J. K., Salemme, F. R., and Todd, M. J. (2005) Thermodynamic stability of carbonic anhydrase. Measurements of binding affinity and stoichiometry using ThermoFluor. *Biochemistry* **44**, 5258–5266

60. Martinez Molina, D., Jafari, R., Ignatushchenko, M., Seki, T., Larsson, E. A., Dan, C., Sreekumar, L., Cao, Y., and Nordlund, P. (2013) Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay. *Science* **341**, 84–87

61. Plass, C., Pfister, S. M., Lindroth, A. M., Bogatyrova, O., Claus, R., and Lichter, P. (2013) Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer. *Nat. Rev. Genet.* **14**, 765–780

62. Bjerke, L., Mackay, A., Nandhabalan, M., Burford, A., Jury, A., Popov, S., Bax, D. A., Carvalho, D., Taylor, K. R., Vinci, M., Bajrami, I., Mcgonnell, I. M., Lord, C. J., Reis, R. M., Hargrave, D., Ashworth, A., Workman, P., and Jones, C. (2013) Histone H3.3 mutations drive pediatric glioblastoma through up-regulation of MYCN. *Cancer Discov.* **3**, 512–519

63. Hewings, D. S., Rooney, T. P., Jennings, L. E., Hay, D. A., Schofield, C. J., Brennan, P. E., Knapp, S., and Conway, S. I. (2012) Progress in the development and application of small molecule inhibitors of bromodomain-acetyl-lysine interactions. *J. Med. Chem.* **55**, 9393–9413

64. Muller, S., Filippakopoulos, P., and Knapp, S. (2011) Bromodomains as therapeutic targets. *Expert Rev. Mol. Med.* **13**, e29

65. Steiner, S., Magno, A., Huang, D., and Caflisch, A. (2013) Does bromodomain flexibility influence histone recognition? *FEBS Lett.* **587**, 2158–2163

66. Sun, H., Liu, J., Zhang, J., Shen, W., Huang, H., Xu, C., Dai, H., Wu, J., and Shi, Y. (2007) Solution structure of BRD7 bromodomain and its interaction with acetylated peptides from histone H3 and H4. *Biochem. Biophys. Res. Commun.* **358**, 435–441

67. Prinjha, R. K., Witherington, J., and Lee, K. (2012) Place your BETs. The therapeutic potential of bromodomains. *Trends Pharmacol. Sci.* **33**, 146–153